Implantable medical devices having anti-restenotic coatings are disclosed.
Specifically, implantable medical devices having coatings of certain
antiproliferative agents, particularly a certain endothelin receptor
inhibitor, are disclosed. The anti-restenotic endothelin receptor
inhibitor is atrasentan, and pharmaceutically acceptable derivatives
thereof. The anti-restenotic medical devices include stents, catheters,
micro-particles, probes and vascular grafts. Intravascular stents are
preferred medical devices. The medical devices can be coated using any
method known in the art including compounding the endothelin receptor
inhibitor with a biocompatible polymer prior to applying the coating.
Moreover, medical devices composed entirely of biocompatible
polymer-endothelin receptor inhibitor blends are disclosed. Additionally,
medical devices having a coating comprising at least one endothelin
receptor inhibitor in combination with at least one additional
therapeutic agent are also disclosed. Furthermore, related methods of
using and making the anti-restenotic implantable devices are also
disclosed.
